GlassScriptPhysician profile
James D Birmingham
NPI 1891811543
$17,825.41
in general payments reported to CMS, 2019-2025
34 companies · $5,994 in 2025
The $5,994 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,425 · 2021: $12.57 · 2022: $315 · 2023: $2,491 · 2024: $7,587 · 2025: $5,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,721 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,675 · Consulting Fee: $2,550 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,720.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,675.00 |
| Consulting Fee | $2,550.00 |
| Education | $127.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,206.98 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,530.94 | 2019-2025 | Enbrel, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $1,133.69 | 2019-2025 | |
| Ucb, INC. | $927.48 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $629.88 | 2023-2025 | Saphnelo |
| Janssen Biotech, INC. | $585.53 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $498.48 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $295.98 | 2023-2025 | Idacio |
| Lilly USA, LLC | $238.29 | 2019-2025 | Taltz, Zepbound |
| Pfizer INC. | $213.50 | 2019-2025 | |
| Sandoz INC. | $199.97 | 2023-2024 | Hyrimoz |
| Organon LLC | $188.53 | 2023-2025 | Renflexis, Hadlima |
| Incyte Corporation | $124.99 | 2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $122.56 | 2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.17 | 2023-2025 | Ofev, Cyltezo, Spevigo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $103.17 | 2019-2023 | Orencia |
| Genentech USA, INC. | $85.15 | 2019 | |
| Bioventus LLC | $83.79 | 2025 | Durolane, Xcell |
| Celgene Corporation | $68.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.17 | 2019 | |
| Janssen Scientific Affairs, LLC | $51.42 | 2019 | |
| Sobi, INC | $47.02 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $40.59 | 2019 | |
| Silvergate Pharmaceuticals, INC. | $38.72 | 2019 | |
| Horizon Therapeutics Plc | $37.31 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $35.75 | 2019 | |
| Onmark, INC. | $30.98 | 2025 | |
| Mallinckrodt Hospital Products INC. | $29.72 | 2024 | Acthar |
| Celltrion USA INC. | $24.14 | 2023 | Yuflyma |
| Ani Pharmaceuticals, INC. | $22.69 | 2025 | Purified Cortrophin Gel |
| Invivyd INC | $20.00 | 2025 | Pemgarda |
| Aurinia Pharma U.S., INC. | $20.00 | 2025 | Lupkynis |
| Kyowa Kirin, INC. | $18.69 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Birmingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.